

PULMONOLOGY

In the pulmonology clinic, there is a unique opportunity for combined (general and local) use of ERBISOL® class medications. Local treatment is carried out by nebulizer inhalations. Tactics of treatment and methods of their use are determined by the attending physician depending on the nature of the nonspecific bronchopulmonary inflammatory process.

1. In complex therapy of acute bronchitis, pneumonia and exacerbation of chronic nonspecific bronchopulmonary diseases, use the standard course of immunomodulation, hepatoprotection, reparation and adaptation with ERBISOL® medication

A course of therapy for 20 days

30 ampoules of ERBISOL® (e)

| Days | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
|-------------------------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|---|
| Time | | | | | | | | | | | | | | | | | | | | | |
| 6 ⁰⁰ - 9 ⁰⁰ | | | | e | e | e | e | e | e | e | e | e | e | | | | | | | | |
| 21 ⁰⁰ - 24 ⁰⁰ | e | e | e | e | e | e | e | e | e | e | e | e | e | e | e | e | e | e | e | e | e |

↓3 days↓

10 days

↓

7 days

↓

During the resolution of the nonspecific bronchopulmonary inflammatory process, it is advisable to apply 10 inhalation sessions of ERBISOL® Extra (overnight ½ ampoule) with nebulizer.

2. In complex therapy of nonspecific bronchopulmonary diseases with the presence of pathogenic microbial-viral associations, use the intensive combined prolonged course of immunotherapy, reparation, hepato-, cardiovascular protection with ERBISOL® ULTRApHarm and ERBISOL® Extra medications

A course of therapy for 31 day

40 ampoules of ERBISOL® ULTRApHarm (u) + 40 ampoules of ERBISOL® Extra (2+)

| Days | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | |
|-------------------------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|--|
| Time | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 ⁰⁰ - 9 ⁰⁰ | | | u | u | u | u | u | u | u | u | u | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | |
| 21 ⁰⁰ - 24 ⁰⁰ | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | u | |

↓2days↓

9 days

↓

10 days

↓

10 days

↓

During the resolution of the nonspecific bronchopulmonary inflammatory process with the presence of pathogenic microbial-viral associations, it is advisable to apply 10 inhalation sessions of ERBISOL® (overnight ½ ampoule) with nebulizer.

3. In therapy of sarcoidosis* of the respiratory organs, use the systemic therapy by standard courses of ERBISOL® medication

*(*The morphological substrate of sarcoidosis is granulomatous inflammation. The main structural unit of the granuloma is a macrophage with an incomplete process of phagocytosis of the antigenic stimulus. A macrophage presentation of such stimulus to helper lymphocytes (CD4 +) causes the production of a complex of cytokines (IL-1, IL-4, IFN-γ). ERBISOL® medication, activating macrophages, directly contributes to the restoration of the full-fledged phagocytic processes and the formation of a full-fledged specific adaptive immune response of the organism. Proceeding from the above, the effect of ERBISOL® medication is a successful etiopathogenetic alternative to the treatment of sarcoidosis with immunosuppressants)*

